Trial Profile
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lurbinectedin (Primary) ; Doxorubicin; Gemcitabine
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 09 Feb 2021 Status changed from active, no longer recruiting to completed.
- 30 Dec 2019 Results published in the European Journal of Cancer
- 26 Apr 2017 Planned End Date changed from 1 Nov 2022 to 1 Nov 2021.